IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out

Ligand Pharmaceuticals has been recognized as IBD's Stock Of The Day following a breakout in its stock price. This surge is attributed to its role in the biotech industry as a royalty generation company. The positive momentum suggests strong investor confidence and potential for continued growth. Market analysts anticipate that Ligand's innovative approach could lead to increased revenue streams. This breakout may attract further attention from both retail and institutional investors, which could boost the stock's performance in the coming weeks.